In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin
Therapy (ESPRIT) trial, treatment with eptifibatide, a platelet glycoprotein
IIb/IIIa integrin blocker, was found to reduce the ischemic complications
of nonurgent coronary stent implantation at 48 hours and 30 days.
To determine whether eptifibatide treatment continues to provide durable,
long-term benefit after coronary stent intervention.
Design and Setting
The ESPRIT trial was a randomized, double-blind, placebo-controlled,
parallel-group, crossover-permitted trial conducted from June 1999 through
February 2000 at 92 tertiary care centers in the United States and Canada.
A total of 2064 patients scheduled to undergo nonurgent percutaneous
coronary intervention with stent implantation.
Patients were randomly assigned to receive placebo (n = 1024) or eptifibatide
(two 180-µg/kg boluses, 10 minutes apart, with a continuous infusion
of 2.0 µg/kg per minute; n = 1040), started immediately before stent
implantation and continued for 18 to 24 hours. Patients also received aspirin,
heparin, and a thienopyridine.
Main Outcome Measures
Composite rates of death or myocardial infarction (MI) and death, infarction,
or target vessel revascularization during the 12 months after enrollment.
Complete follow-up data were available for 988 patients given eptifibatide
(95.0%) and 976 patients given placebo (95.3%). By 12 months, the composite
of death or MI had occurred in 8.0% of eptifibatide-treated patients and in
12.4% of placebo-treated patients (hazard ratio [HR], 0.63; 95% confidence
interval [CI], 0.48-0.83; P = .001). The composite
rate of death, MI, or target vessel revascularization was 17.5% in eptifibatide-treated
patients vs 22.1% in placebo-treated patients (HR, 0.76; 95% CI, 0.63-0.93; P = .007).
Long-term outcomes of nonurgent coronary stent implantation appear to
be improved through blockade of the platelet glycoprotein IIb/IIIa integrin